HCI Group walks into its earnings call with fresh numbers and a market already asking whether the beat is priced in.
Q1 2026 EPS came in at $5.45, topping the $4.96 consensus estimate. Revenue hit $242.9 million, also ahead of the $238.9 million Street expectation. That double beat — reported after the close on May 6 — follows a first quarter in which the stock had already recovered 1.1% on the month, closing at $154.78 after a 3.7% bounce on May 5. The week as a whole was still down 2.1%, leaving the setup into results modestly uncertain.
The short book tells a calm story. Short interest is a modest 2.2% of free float — low enough that bearish pressure from positioning alone is not a meaningful driver here. What is striking is the trajectory: shorts roughly tripled from around 78,000 shares in late April to nearly 280,000 by early May, a move of more than 250% over just a week. Even so, the absolute level remains small relative to the float. Availability is extremely loose, with borrow utilisation barely above 1% against a 52-week peak of 27.4%. Cost to borrow dropped sharply to 0.29% on May 5 from around 0.46% the prior week — the lending market is not signalling any stress. The ORTEX short score of 31.4 sits in roughly the 62nd percentile for short score rank, a modestly elevated but not extreme reading.
Options positioning is slightly more cautious than usual, though not dramatically so. The put/call ratio moved up to 0.34 on May 5, running a little above its 20-day average of 0.32. The z-score of 1.1 means investors have nudged toward protection but nowhere near the degree of hedging that would suggest real anxiety. The 52-week range on the PCR runs from 0.05 to 0.42 — the current reading is well within normal territory. Caution is present; it is not pronounced.
The analyst picture is dated but directionally useful. The last recorded changes — from Oppenheimer, Citizens, and Truist Securities — date to November 2025, more than six months ago. At that point, Oppenheimer trimmed HCI to a neutral Perform rating, while Citizens raised its target to $255 and Truist lifted to $235. Two active buy-side ratings remain on the stock, with the mean price target of $245 implying roughly 58% upside to the current price at $154.78. The valuation case is straightforward: trailing P/E of approximately 10.8x and a price-to-book of roughly 2.0x are both compressing gradually, with P/E off about 0.3 points over the past 30 days. EPS surprise ranks in the 89th percentile historically — HCI has a strong habit of clearing the bar — a pattern reinforced by last night's beat. Factor scores also flag strong dividend rank (89th percentile) and days-to-cover rank (81st percentile), though dividend data beyond 2022 is absent from the snapshot, so recent yield should be verified independently.
The two most recent earnings reactions in the history data are instructive as a reference point, not a forecast. In February 2026, the stock gained 8.7% on the day after results before extending to an 11.3% five-day return. The prior event in that dataset saw a 2.1% next-day gain that faded to a marginal loss over the following week. The range of outcomes is wide. Institutional ownership is broad and relatively passive — BlackRock at 13.7%, Vanguard at 6.5%, and American Century adding 51,645 shares as of April 30 are the most recent active moves of note. Among peers, UVE and AIG both tracked broadly similar intraday moves on May 5, though KINS and KFS had a rougher week, falling 10.5% and 8.8% respectively — suggesting sector conditions are not uniformly supportive.
What to watch next is whether the beat — solid on both lines — is enough to move analysts off their six-month silence and prompt fresh target upgrades, and whether the stock can hold above its recent range given the broader softness in smaller insurance names this week.
See the live data behind this article on ORTEX.
Open HCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
